Factors affecting intrasubject variability of PK exposure: absolute oral bioavailability and acidic nature of drugs [0.03%]
影响药代动力学暴露值组内变异性的因素：口服生物利用度及药物的酸性性质的影响
Masahiko Sato,Mamoru Narukawa
Masahiko Sato
Objectives: The aim of the present study is to investigate factors affecting intrasubject variability of pharmacokinetic (PK) exposure, which affect the results of bioequivalence (BE) studies. We focused on two factors: a...
Investigation of a potential pharmacokinetic interaction between perindopril arginine and amlodipine when administered as a single perindopril/amlodipine fixed-dose combination tablet in healthy Chinese male volunteers [0.03%]
贝那普利艾 Argentine/氨氯地平单片固定剂量组合在健康中国男性受试者中的药动学相互作用研究
Xin Zheng,Tao Liu,Xia Chen et al.
Xin Zheng et al.
Objectives: To determine whether a potential pharmacokinetic interaction exists between perindopril arginine 5 mg and amlodipine 5 mg, after administration as a fixed-combination of perindopril 5 mg/amlodipine 5 mg (S0598...
Randomized Controlled Trial
International journal of clinical pharmacology and therapeutics. 2016 Jan;54(1):43-51. DOI:10.5414/CP202250 2016
Absorption, distribution, metabolism, and excretion of [14C]-labeled naloxegol in healthy subjects [0.03%]
纳洛茁人体内的吸收、分布、代谢和排泄研究
Khanh Bui,Fahua She,Michael Hutchison et al.
Khanh Bui et al.
Objective: To characterize the absorption, distribution, metabolism, and excretion of naloxegol, a PEGylated derivative of the µ-opioid antagonist naloxone, in healthy male subjects. ...
Good publication practices in clinical pharmacology: transparency, evidence-based medicine and the 7-D assessment [0.03%]
临床药理学良好出版实践：透明性、循证医学与7维评估
Barry G Woodcock,Veronika Luger
Barry G Woodcock
Transparency and evidence-based medicine are cornerstones of good publication practices (GPP), and concern publishers, editors, research investigator, and reviewers alike. Methods for implementing these principles within the framework of GP...
Comparative effectiveness and tolerability of esomeprazole and omeprazole in gastro-esophageal reflux disease: A systematic review and meta-analysis [0.03%]
埃索美拉唑与奥美拉唑治疗胃食管反流病疗效和耐受性的对比：系统评价和网络meta分析
Qian Qi,Rugang Wang,Lin Liu et al.
Qian Qi et al.
This study aims to evaluate the effectiveness and tolerability of esomeprazole and omeprazole in patients with gastroesophageal reflux disease (GERD). Electronic searches on PubMed, EMBASE, the Cochrane Library, and ClinicalTrials.gov datab...
Pharmacokinetics of a telmisartan/rosuvastatin fixed-dose combination: a single-dose, randomized, open-label, 2-period crossover study in healthy Korean subjects [0.03%]
坎地沙坦酯/罗苏伐他汀固定剂量复方制剂的药物代谢动力学：健康受试者中的单次给药、随机、开放性、两周期交叉研究
Dong Woo Chae,Mijeong Son,Yukyung Kim et al.
Dong Woo Chae et al.
Objective: As hypertension and dyslipidemia are frequent comorbidities, antihypertensive drugs and lipid-lowering agents are often prescribed together for their treatment. Telmisartan and rosuvastatin are widely used toge...
Randomized Controlled Trial
International journal of clinical pharmacology and therapeutics. 2015 Oct;53(10):883-9. DOI:10.5414/CP202412 2015
Efficacy of calcitriol compared to alfacalcidol for the treatment of secondary hyperparathyroidism in peritoneal dialysis patients [0.03%]
腹膜透析患者继发性甲旁亢患者活性维生素D类似物治疗疗效的比较研究
Sarah Bezzaoucha,Jean-Philippe Lafrance,Denis Ouimet et al.
Sarah Bezzaoucha et al.
Potentially inappropriate medication use at ambulatory care visits by elderly patients covered by National Health Insurance in Korea [0.03%]
韩国老年人医保参保人在门诊就诊时使用潜在不适当药物的情况
Dong-Sook Kim,Soonim Huh,Sukhyang Lee
Dong-Sook Kim
Objectives: Potentially inappropriate medication (PIM) use is an important and preventable safety concern in the care of elderly patients and has been associated with adverse drug reactions, hospitalization, and mortality...
Lack of effect of favipiravir, a novel antiviral agent, on QT interval in healthy Japanese adults [0.03%]
新型抗病毒药物法维拉韦对健康日本成人QT间期无影响
Yuji Kumagai,Yuji Murakawa,Tomoko Hasunuma et al.
Yuji Kumagai et al.
Objective: A thorough QT study of favipiravir, a novel antiviral agent, was conducted using a randomized, doubleblind, 4-group, 4-period crossover, placebo-and positive-controlled (open-label moxifloxacin) design. ...
Randomized Controlled Trial
International journal of clinical pharmacology and therapeutics. 2015 Oct;53(10):866-74. DOI:10.5414/CP202388 2015
Population pharmacokinetics of tenofovir in HIV/HBV co-infected patients [0.03%]
HIV和HBV合并感染患者中替诺福韦的群体药代动力学特征
Baralee Punyawudho,Narukjaporn Thammajaruk,Parawee Thongpeang et al.
Baralee Punyawudho et al.
Objective: Tenofovir is an efficacious drug with a long half-life and high activity against both HIV and HBV. However, the pharmacokinetics of tenofovir have not been studied in HIV/HBV co-infected patients. Data from HIV...